Suppr超能文献

在小鼠肝细胞癌变过程中蛋白酶体库的变化。

Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.

机构信息

Koltsov Institute for Developmental Biology, Russian Academy of Sciences.

出版信息

Acta Naturae. 2010 Apr;2(1):102-8.

Abstract

Multiple forms of proteasomes regulate cellular processes by destroying proteins or forming the peptides involved in those processes. Various pathologies, including carcinogenesis, are related to changes in the functioning of the proteasome forms. In this study, we looked at the changes in the pool of liver proteasomes during nodular regenerative hyperplasia and formation of adenoma and hepatocellular carcinoma in mice treated with Dipin, followed by partial liver resection. The relative content of various proteasome forms was determined using Western blot analysis. The chymotrypsin-like activity of proteasomes was assessed from the hydrolysis of the commercial Suc-LLVY-AMC substrate. It was found that changes in the proteasome pool appeared already during the formation of diffuse nodules, the changes being the increased expression of the X(β5) constitutive subunit and the LMP7(β5i) and LMP2(β1i) immune subunits, accompanied by the increase of the total proteasome pool and the decrease in the chymotrypsin-like activity. These changes were more pronounced in hepatocellular carcinoma. The content of the total proteasome pool and the LMP2(β1i) immune subunit and the chymotrypsin-like activity in adenoma were intermediate compared to those in the samples of liver with diffuse nodules and carcinoma. In addition, the level of the Rpt6 subunit present in the 19S proteasome activator was increased in carcinoma. Our results indicate that nodular regenerative hyperplasia and adenomatosis may be stages preceding carcinogenesis. We also conclude that there is a need to find signalling pathways that change the expression of various proteasome subunits during carcinogenesis. The 19S proteasome activator, which is overexpressed in malignant tumours, can be a promising target for the development of new anticancer drugs.

摘要

多种形式的蛋白酶体通过破坏蛋白质或形成参与这些过程的肽来调节细胞过程。包括癌变在内的各种病理学与蛋白酶体形式功能的变化有关。在这项研究中,我们观察了在用 Dipin 处理的小鼠的结节性再生性增生、腺瘤和肝细胞癌形成过程中,肝脏蛋白酶体库的变化,随后进行了部分肝切除术。使用 Western blot 分析确定了各种蛋白酶体形式的相对含量。通过水解商业 Suc-LLVY-AMC 底物评估蛋白酶体的糜蛋白酶样活性。结果发现,蛋白酶体库的变化早在弥漫性结节形成时就出现了,变化是 X(β5)组成型亚基和 LMP7(β5i)和 LMP2(β1i)免疫亚基的表达增加,伴随着总蛋白酶体库的增加和糜蛋白酶样活性的降低。这些变化在肝细胞癌中更为明显。与弥漫性结节和癌组织样本相比,腺瘤的总蛋白酶体库含量、LMP2(β1i)免疫亚基和糜蛋白酶样活性较低。此外,19S 蛋白酶体激活剂中存在的 Rpt6 亚基水平在癌组织中增加。我们的结果表明,结节性再生性增生和腺瘤可能是癌变前的阶段。我们还得出结论,需要找到在癌变过程中改变各种蛋白酶体亚基表达的信号通路。在恶性肿瘤中过度表达的 19S 蛋白酶体激活剂可以成为开发新抗癌药物的有前途的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/c7d96820cffa/AN20758251-04-102-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验